search
Back to results

NPWT PRO vs KCI Ulta® NPWT and to Compare NPWT PRO vs NPWT PRO With Simultaneous Irrigation on Wound Healing

Primary Purpose

Partial-thickness Burn, Ulcer

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
NPWT PRO without irrigation
NPWT PRO with irrigation
KCI Ulta
Sponsored by
Larry Lavery
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Partial-thickness Burn focused on measuring diabetic ulcer, pressure ulcer, chronic or traumatic wound, sub-acute or dehisced wound

Eligibility Criteria

18 Years - 89 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Presents with an existing chronic or traumatic wound, sub-acute or dehisced wound, partial-thickness burn, ulcer (such as a diabetic or pressure ulcer), flap or graft as diagnosed by a qualified and certified medical practitioner (M.D., D.O., or D.P.M)
  • Wound presents with full thickness loss of epidermis and dermis
  • The presentation of a wound that in the opinion of the investigators will require surgical debridement, and the wound is expected to be a good candidate for NPWT and eventual wound closure.
  • ABI≥0.5 or toe pressures >30 PVR/mmHg
  • Subject is willing and able to abstain from partaking in any other form of treatment for his or her wound throughout the duration of his or her course of participation in the clinical study, other than the study procedures described herein.
  • 18 years of age or older

Exclusion Criteria:

  • Does not present with an existing chronic or traumatic wound, sub-acute or dehisced wound, partial-thickness burn, ulcer (such as a diabetic or pressure ulcer), flap or graft, or a definitive diagnosis cannot be made, as diagnosed by a qualified and certified medical practitioner (M.D., D.O., or D.P.M)
  • Wound does not present with full thickness loss of epidermis and dermis
  • ABI<0.5 or toe pressures <30 PVR/mmHg
  • Subject is not willing or is not able or it is not medically prudent for the subject to abstain from partaking in any other form of treatment for his or her wound throughout the duration of his or her course of participation in the clinical study, other than the study procedures described.
  • Subject is unwilling or unable to use the NPWT device at home
  • Active Charcot arthropathy
  • Collagen vascular disease
  • Scleroderma
  • Non-enteric and unexplored fistula
  • Necrotic tissue with eschar present after debridement
  • General skin disorder in the area of the wound such as psoriasis or penicilitis
  • Malnutrition (defined as BMI <19)
  • Hypercoagulable state based on documentation in their medical record
  • Acute deep vein thrombosis
  • Current active malignancy in the wound
  • Current melanoma or history of melanoma at the wound
  • Current active or history of invasive squamous cell carcinoma at the wound
  • Sepsis (defined as positive blood culture with leukocytosis) and temperature >101.5 at the time of screening
  • Significant Hematologic disorders EXCLUDING anemia
  • HIV
  • Fever at screening > 101.5
  • Deep X-ray therapy
  • Untreated bone or soft tissue infection (osteomyelitis)
  • Any concomitant illness(es) or medical condition(s) that in the opinion of the investigator would render the subject not suited for study participation
  • Subject is taking a regimen of any medication(s) in a significant enough dosage that may affect chronic wound healing, including corticosteroid, chemotherapeutic and non-steroidal anti-inflammatory (NSAID) medications
  • Less than 18 years of age
  • Developmental disability/significant psychological disorder that could impair the subject's ability to provide informed consent, participate in the study protocol or record study measures, including schizophrenia, bipolar disorder and psychiatric hospitalization within the last 2 years.
  • Females currently pregnant or planning pregnancy during the course of intended participation in the study
  • Active alcohol or substance abuse in the opinion of the investigator that could impair the subjects ability to provide informed consent, participate in the study protocol or record study measures.

Sites / Locations

  • UT Southwestern Medical Center
  • UT Southwestern

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Active Comparator

Arm Label

NPWT PRO without irrigation

NPWT PRO with Irrigation

KCI Ulta NPWT

Arm Description

Cardinal Health NPWT PRO system (K143016) continuous/intermittent vacuum-assisted drainage

Cardinal Health NPWT PRO system (K143016) continuous/intermittent vacuum-assisted drainage with simultaneous delivery of topical wound treatment solutions and suspensions over the wound bed (saline irrigant).

KCI Ulta NPWT without irrigation.

Outcomes

Primary Outcome Measures

Number of Participants Who Achieved Complete Wound Healing
Complete healing of wounds as defined by epithelialization with no drainage in three treatment arms: NPWT PRO versus KCI Ulta® NPWT and to Compare NPWT PRO versus NPWT PRO with Simultaneous Irrigation

Secondary Outcome Measures

Number of Surgeries
Number of surgeries required to debride infection before wound was ready for closure or coverage.
Length of Stay
Number of days the patient stayed in the hospital
Days to Heal
The number of days to heal the wound after last surgery was performed.

Full Information

First Posted
June 1, 2015
Last Updated
July 20, 2023
Sponsor
Larry Lavery
search

1. Study Identification

Unique Protocol Identification Number
NCT02519621
Brief Title
NPWT PRO vs KCI Ulta® NPWT and to Compare NPWT PRO vs NPWT PRO With Simultaneous Irrigation on Wound Healing
Official Title
A Pilot Study to Compare the Efficacy of NPWT PRO Versus KCI Ulta® NPWT and to Compare NPWT PRO Versus NPWT PRO With Simultaneous Irrigation on Wound Healing
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Completed
Study Start Date
April 2016 (Actual)
Primary Completion Date
January 2019 (Actual)
Study Completion Date
June 24, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Larry Lavery

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is designed to assess the efficacy and economics of two NPWT (negative pressure wound therapy) branded devices of wound healing outcomes. It is also designed to assess the effectiveness of negative pressure and negative pressure with continuous irrigation on multiple parameters of wound healing. It is a single-center, open-label, active controlled, parallel-group trial that aims to determine the efficacy of Quantum with simultaneous irrigation in the treatment of diabetic foot ulcers. Specifically, eligible participants will be randomized to receive either PRO negative press therapy with simultaneous irrigation; or PRO negative pressure therapy without irrigation; or KCI Ulta negative pressure therapy. Outcomes will include rates of wound healing, time to closure, number of surgeries, length of stay, and days to heal.
Detailed Description
Subjects will be taken to the operating room for the initial debridement procedure of the wound. At the end of the procedure, subjects who continue to meet all inclusion and no exclusion criteria will be randomized in a 1:1:1 ratio to be treated with either PRO, PRO with simultaneous irrigation (PROI), or KCI Ulta NPWT. Prior to study initiation sealed prenumbered randomization envelopes will be provided to the research staff and used to obtain randomization assignment. Opening of the randomization envelope will occur intraoperatively at the conclusion of the initial surgical debridement of the wound and conformation of all eligibility requirements. Study staff will use the randomization number labels contained in the envelop. The number will become the subject ID. The assignment will be subjects randomized to PRO, PRO with simultaneous irrigation, or KCI Ulta NPWT. The research staff will note treatment assignments on the intra operative randomization CRF and instruct the investigator. Treatment therapy wound dressings will be applied in the operating room or in the patient's room immediately after surgery per the investigators discretion, according to the manufacturer's recommendations. In order to ensure consistent study treatment, subjects will receive assigned treatment therapies within their study arm after the initial and any subsequent surgical debridements until the wound is deemed ready for closure or coverage by the Investigator. Subjects randomized to the PRO with simultaneous irrigation Treatment arm are the only subjects that will receive irrigation therapy at any time during the study treatment period. If irrigation therapy is discontinued, subjects in the Treatment arm will transition to PRO NPWT without irrigation. Subjects randomized to the PRO Control arm will receive NPWT only from the PRO therapy unit.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Partial-thickness Burn, Ulcer
Keywords
diabetic ulcer, pressure ulcer, chronic or traumatic wound, sub-acute or dehisced wound

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
90 (Actual)

8. Arms, Groups, and Interventions

Arm Title
NPWT PRO without irrigation
Arm Type
Active Comparator
Arm Description
Cardinal Health NPWT PRO system (K143016) continuous/intermittent vacuum-assisted drainage
Arm Title
NPWT PRO with Irrigation
Arm Type
Active Comparator
Arm Description
Cardinal Health NPWT PRO system (K143016) continuous/intermittent vacuum-assisted drainage with simultaneous delivery of topical wound treatment solutions and suspensions over the wound bed (saline irrigant).
Arm Title
KCI Ulta NPWT
Arm Type
Active Comparator
Arm Description
KCI Ulta NPWT without irrigation.
Intervention Type
Device
Intervention Name(s)
NPWT PRO without irrigation
Other Intervention Name(s)
Cardinal Quantum NPWT PRO
Intervention Description
NPWT PRO without irrigation.
Intervention Type
Device
Intervention Name(s)
NPWT PRO with irrigation
Other Intervention Name(s)
Cardinal Quantum NPWT PRO
Intervention Description
NPWT PRO with irrigation (saline)
Intervention Type
Device
Intervention Name(s)
KCI Ulta
Intervention Description
KCI Ulta NPWT without irrigation
Primary Outcome Measure Information:
Title
Number of Participants Who Achieved Complete Wound Healing
Description
Complete healing of wounds as defined by epithelialization with no drainage in three treatment arms: NPWT PRO versus KCI Ulta® NPWT and to Compare NPWT PRO versus NPWT PRO with Simultaneous Irrigation
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Number of Surgeries
Description
Number of surgeries required to debride infection before wound was ready for closure or coverage.
Time Frame
12 weeks
Title
Length of Stay
Description
Number of days the patient stayed in the hospital
Time Frame
12 weeks
Title
Days to Heal
Description
The number of days to heal the wound after last surgery was performed.
Time Frame
12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
89 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Presents with an existing chronic or traumatic wound, sub-acute or dehisced wound, partial-thickness burn, ulcer (such as a diabetic or pressure ulcer), flap or graft as diagnosed by a qualified and certified medical practitioner (M.D., D.O., or D.P.M) Wound presents with full thickness loss of epidermis and dermis The presentation of a wound that in the opinion of the investigators will require surgical debridement, and the wound is expected to be a good candidate for NPWT and eventual wound closure. ABI≥0.5 or toe pressures >30 PVR/mmHg Subject is willing and able to abstain from partaking in any other form of treatment for his or her wound throughout the duration of his or her course of participation in the clinical study, other than the study procedures described herein. 18 years of age or older Exclusion Criteria: Does not present with an existing chronic or traumatic wound, sub-acute or dehisced wound, partial-thickness burn, ulcer (such as a diabetic or pressure ulcer), flap or graft, or a definitive diagnosis cannot be made, as diagnosed by a qualified and certified medical practitioner (M.D., D.O., or D.P.M) Wound does not present with full thickness loss of epidermis and dermis ABI<0.5 or toe pressures <30 PVR/mmHg Subject is not willing or is not able or it is not medically prudent for the subject to abstain from partaking in any other form of treatment for his or her wound throughout the duration of his or her course of participation in the clinical study, other than the study procedures described. Subject is unwilling or unable to use the NPWT device at home Active Charcot arthropathy Collagen vascular disease Scleroderma Non-enteric and unexplored fistula Necrotic tissue with eschar present after debridement General skin disorder in the area of the wound such as psoriasis or penicilitis Malnutrition (defined as BMI <19) Hypercoagulable state based on documentation in their medical record Acute deep vein thrombosis Current active malignancy in the wound Current melanoma or history of melanoma at the wound Current active or history of invasive squamous cell carcinoma at the wound Sepsis (defined as positive blood culture with leukocytosis) and temperature >101.5 at the time of screening Significant Hematologic disorders EXCLUDING anemia HIV Fever at screening > 101.5 Deep X-ray therapy Untreated bone or soft tissue infection (osteomyelitis) Any concomitant illness(es) or medical condition(s) that in the opinion of the investigator would render the subject not suited for study participation Subject is taking a regimen of any medication(s) in a significant enough dosage that may affect chronic wound healing, including corticosteroid, chemotherapeutic and non-steroidal anti-inflammatory (NSAID) medications Less than 18 years of age Developmental disability/significant psychological disorder that could impair the subject's ability to provide informed consent, participate in the study protocol or record study measures, including schizophrenia, bipolar disorder and psychiatric hospitalization within the last 2 years. Females currently pregnant or planning pregnancy during the course of intended participation in the study Active alcohol or substance abuse in the opinion of the investigator that could impair the subjects ability to provide informed consent, participate in the study protocol or record study measures.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lawrence A Lavery, DPM
Organizational Affiliation
UT Southwestern Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
UT Southwestern Medical Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390
Country
United States
Facility Name
UT Southwestern
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390
Country
United States

12. IPD Sharing Statement

Learn more about this trial

NPWT PRO vs KCI Ulta® NPWT and to Compare NPWT PRO vs NPWT PRO With Simultaneous Irrigation on Wound Healing

We'll reach out to this number within 24 hrs